Neumora Therapeutics, Inc.

Neumora is a clinical-stage biopharmaceutical company focused on developing novel therapies with brain-penetrant chemistry. The company's therapeutic pipeline targets a range of underserved, prevalent diseases, including neurodegenerative diseases, neuropsychiatric diseases, and metabolic disorders. Neumora is advancing a Phase 3 program for navacaprant, a once-daily oral kappa opioid receptor ("KOR") antagonist, for the treatment of major depressive disorder ("MDD"). Additionally, the company is developing NMRA-511, a highly selective antagonist of the vasopressin 1a receptor ("V1aR"), for the treatment of agitation associated with dementia due to Alzheimer's disease ("AD"). Neumora's pipeline also includes NMRA-898, a novel M4 PAM for the treatment of schizophrenia, and NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor for the treatment of obesity. The company expects to report Phase 3 KOASTAL-2 and -3 topline data in the second quarter of 2026, MAD extension data with NMRA-511 in the second half of 2026, and multiple ascending dose ("MAD") data with NMRA-898 in the second half of 2026. Neumora has scaled its pipeline through internal discovery and business development activities.